AdAlta’s management team has been responsible for the development of the i-body technology platform, including the identification and pre-clinical development of the lead i-body drug candidate. AdAlta’s management team is focused on progressing the lung fibrosis therapy, AD-214, into the clinic.
Tim Oldham PhD
CEO & Managing Director
Tim has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products. Tim was appointed CEO and MD in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Company. Industry leadership roles include currently serving as a Director of BioMelbourne Network Inc and terms as chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association. He is a Non-executive Director at Acrux Ltd (ASX:ACR).
Angus Tester PhD
Senior Director, Operations
Angus is the Senior Director of Operations at AdAlta and has over 20 years’ experience in the biotechnology field. Prior to joining AdAlta, Angus worked for multiple successful ASX listed biotechnology companies including Opthea, Nexvet, Telix and Exopharm. Angus has held multiple managerial roles, developing extensive product development and project management expertise spanning preclinical, clinical, CMC and regulatory activities. Before moving to industry, Angus undertook postdoctoral research at the University of British Columbia in Vancouver and at St Vincent’s Institute of Medical Research in Melbourne, after completing his PhD at Monash University in Melbourne.
Janette Dixon DBA
Head of Business Development
Leveraging more than 25 years of experience in chief executive roles and as a management consultant, Janette specialises in leading the partnering of pharmaceutical assets and technologies and founding biotech companies based on compelling new science. She has extensive business development and licensing experience across Asia Pacific including China, North America and Europe. Janette’s doctoral research focused on understanding commercialisation strategy in biotech start-ups, providing unique insights into the relationships between technologies and business models.
Darryn Bampton
Director Clinical and Regulatory Operations
Darryn has 28 years’ experience in the biotechnology industry, principally in regulatory affairs and clinical development roles across small biotechnology and large pharmaceutical companies. Since 2012, he has been the Director of a Drug Development consulting company, Bampton Regulatory Services. Recent achievements include oversight of the clinical programme for the immunomodulator pixatimod, which is currently in Phase 2 clinical trials and regulatory affairs roles in cross-functional drug development teams for several marketed products, including the orphan oncology drug Savene (TopoTarget). Previously, he held senior management positions at Progen Pharmaceuticals Limited and Constella Group.